Arrestin Pathways as Drug Targets - Progress in Molecular Biology and Translational Science - page 476

ACKNOWLEDGMENTS
Supported in part by National Institutes of Health Grant DK55524 (L. M. L.) and the
Research Service of the Charleston, SC Veterans Affairs Medical Center. The contents of
this chapter do not represent the views of the Department of Veterans Affairs or the
United States Government.
REFERENCES
1. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic recep-
tor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the
pluridimensionality of efficacy. Mol Pharmacol . 2006;70:1575- 1584.
2. Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in
G protein-coupled receptor signaling. J Pharmacol Exp Ther . 2005;314:485- 494.
3. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of
arrestin-dependent signaling. Pharmacol Rev . 2010;62:305- 330.
4. Shenoy SK, Lefkowitz RJ. b -Arrestin-mediated receptor trafficking and signal trans-
duction. Trends Pharmacol Sci . 2011;32:521- 533.
5. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of b -arrestin- and
G protein-biased agonists. Trends Mol Med . 2011;7:126- 139.
6. Kenakin T. Agonist-receptor efficacy. II. Agonist-trafficking of receptor signals. Trends
Pharmacol Sci . 1995;16:232- 238.
7. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing.
Pharmacol Rev . 2002;54:323- 374.
8. Kenakin TP. Functional selectivity through protean and biased agonism: who steers the
ship? Mol Pharmacol . 2007;72:1393- 1401.
9. Kenakin T, Miller LE. Seven transmembrane receptors as shapeshifting proteins: the
impact of allosteric modulation and functional selectivity on new drug discovery.
Pharmacol Rev . 2010;62:265- 304.
10. Luttrell LM, Kenakin TP. Refining efficacy: allosterism and bias in G protein-coupled
receptor signaling. Methods Mol Biol . 2011;756:3 - 35.
11. Maudsley S, Patel SA, Park S-S, Luttrell LM, Martin B. Functional signaling biases in
G protein-coupled receptors: game theory and receptor dynamics. Mini Rev Med Chem .
2012;12:831 - 840.
12. Black JW, Leff P. Operational models of pharmacological agonist. Proc R Soc Lond
(Biol) . 1983;220:141 - 162.
13. Black JW, Leff P, Shankley NP. An operational model of pharmacological agonism: the
effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol .
1985;84:561 - 571.
14. Karlin A. On the application of “a plausible model” of allosteric proteins to the receptor
for acetylcholine. J Theor Biol . 1967;16:306 - 320.
15. Thron CD. On the analysis of pharmacological experiments in terms of an allosteric
receptor model. Mol Pharmacol . 1973;9:1 - 9.
16. Kenakin TP. Receptor conformational induction versus selection: all part of the same
energy landscape. Trends Pharmacol Sci . 1996;17:190 - 191.
17. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors
coupled to GTP-binding proteins. Proc Natl Acad Sci USA . 1989;86:7321 - 7325.
18. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of
the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem .
1993;268:4625 - 4636.
19. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-
occupancy model. III. Resurrecting efficacy. J Theor Biol . 1996;181:381 - 397.